Biochemical markers of alcohol use and abuse: experiences from the Pilot Study of the WHO/ISBRA Collaborative Project on state and trait markers of alcohol. International Society for Biomedical Research on Alcoholism.
The development of reliable diagnostic tools for assessing alcoholism and harmful alcohol consumption is an utmost necessity for the success of efforts to prevent and treat alcohol-induced damage to both individuals and to society. A multinational study is underway to aid in the development of biological screening tools (state markers) which can, with good sensitivity and specificity, identify problem drinkers. To attain this goal information needs to be available on an individuals's drinking history and habits and related factors. A detailed instrument has been developed to obtain this information. The second goal of the study was to begin to develop diagnostic 'trait markers' which provide biological information on genetically determined predisposing and protective factors in the development of alcoholism. The developed questionnaire also provides background information on subject characteristics necessary for the development of trait markers. Centres will assay the obtained biological samples for 'traditional' and newly identified state markers of excessive alcohol consumption. These will include methanol measurements, gamma-glutamyltransferase, aspartate aminotransferase, carbohydrate-deficient transferrin, serotonin metabolite ratios, and erythrocyte aldehyde dehydrogenase. DNA obtained from the lymphocytes of subjects will be assayed for polymorphisms of alcohol- and aldehyde-metabolizing enzymes and dopamine receptor polymorphisms which can provide insights into protective and predisposing factors in alcoholism. The platelet enzymes, monoamine oxidase and adenylyl cyclase, will be assayed to assess the relationships between these putative trait markers and the genetic and environmental factors contributing to the aetiology of alcoholism. The current report is meant to introduce the study design and present a portion of the preliminary data gathered in the process of establishing this research programme.
Helander
A
A
Karolinska Institute, Department of Clinical Neuroscience, St Görans Hospital, Stockholm, Sweden.
Tabakoff
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000437:Alcoholism / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D000444:Aldehyde Dehydrogenase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000201:enzymology; D004798:Enzymes / Q000097:blood* / Q000235:genetics; D004912:Erythrocytes / Q000201:enzymology; D000431:Ethanol / Q000493:pharmacokinetics; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D006917:Hydroxytryptophol / Q000097:blood; D008297:Male; D000432:Methanol / Q000493:pharmacokinetics; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014168:Transferrin / Q000031:analogs & derivatives / Q000032:analysis; D005723:gamma-Glutamyltransferase / Q000097:blood
D015415:Biomarkers; D004798:Enzymes; D005819:Genetic Markers; D014168:Transferrin; C056759:carbohydrate-deficient transferrin; D006917:Hydroxytryptophol; D000431:Ethanol; D006897:Hydroxyindoleacetic Acid; D000444:Aldehyde Dehydrogenase; D008995:Monoamine Oxidase; D005723:gamma-Glutamyltransferase; D000410:Alanine Transaminase; D000432:Methanol